719Tip SunRISe-1: Phase IIb Study of TAR-200 in Combination with Cetrelimab (CET), TAR-200 Alone, or CET Alone in Participants with High Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy